These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 21080736)

  • 1. A review and critique of studies reporting utility values for schizophrenia-related health states.
    Mavranezouli I
    Pharmacoeconomics; 2010; 28(12):1109-21. PubMed ID: 21080736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
    Griebsch I; Coast J; Brown J
    Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Review of the Methods Used to Generate Utility Values in NICE Technology Assessments for Children and Adolescents.
    Hill H; Rowen D; Pennington B; Wong R; Wailoo A
    Value Health; 2020 Jul; 23(7):907-917. PubMed ID: 32762993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does the EQ-5D measure quality of life in schizophrenia?
    Halling Hastrup L; Nordentoft M; Hjorthøj C; Gyrd-Hansen D
    J Ment Health Policy Econ; 2011 Dec; 14(4):187-96. PubMed ID: 22345360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of SF-6D and EQ-5D utility scores in a study of patients with schizophrenia.
    McCrone P; Patel A; Knapp M; Schene A; Koeter M; Amaddeo F; Ruggeri M; Giessler A; Puschner B; Thornicroft G
    J Ment Health Policy Econ; 2009 Mar; 12(1):27-31. PubMed ID: 19346564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mapping to obtain EQ-5D utility values for use in NICE health technology assessments.
    Longworth L; Rowen D
    Value Health; 2013; 16(1):202-10. PubMed ID: 23337232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Valuing health-related quality of life in heart failure: a systematic review of methods to derive quality-adjusted life years (QALYs) in trial-based cost-utility analyses.
    Rankin J; Rowen D; Howe A; Cleland JGF; Whitty JA
    Heart Fail Rev; 2019 Jul; 24(4):549-563. PubMed ID: 30903357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility values in National Institute for Health and Clinical Excellence (NICE) Technology Appraisals.
    Tosh JC; Longworth LJ; George E
    Value Health; 2011 Jan; 14(1):102-9. PubMed ID: 21211492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of EQ-5D-3L with QLU-C10D in Metastatic Melanoma Using Cost-Utility Analysis.
    Kim H; Cook G; Goodall S; Liew D
    Pharmacoecon Open; 2021 Sep; 5(3):459-467. PubMed ID: 33891268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health state utility values in schizophrenia: protocol for a systematic review and meta-analysis.
    Aceituno D; Pennington M; Iruretagoyena B; Prina MA; McCrone P
    Evid Based Ment Health; 2019 Nov; 22(4):142-144. PubMed ID: 31126911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Utility Analysis Using EQ-5D-5L Data: Does How the Utilities Are Derived Matter?
    Yang F; Devlin N; Luo N
    Value Health; 2019 Jan; 22(1):45-49. PubMed ID: 30661633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of QALY weights for QALY calculations: a review of industry submissions requesting listing on the Australian Pharmaceutical Benefits Scheme 2002-4.
    Scuffham PA; Whitty JA; Mitchell A; Viney R
    Pharmacoeconomics; 2008; 26(4):297-310. PubMed ID: 18370565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mapping the Functional Independence Measure to a multi-attribute utility instrument for economic evaluations in rehabilitation: a secondary analysis of randomized controlled trial data.
    Peiris CL; Taylor NF; Watts JJ; Shields N; Brusco NK; Mortimer D
    Disabil Rehabil; 2020 Oct; 42(21):3024-3032. PubMed ID: 30907143
    [No Abstract]   [Full Text] [Related]  

  • 14. A hybrid modelling approach for eliciting health state preferences: the Portuguese EQ-5D-5L value set.
    Ferreira PL; Antunes P; Ferreira LN; Pereira LN; Ramos-Goñi JM
    Qual Life Res; 2019 Dec; 28(12):3163-3175. PubMed ID: 31201730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparing and transforming PROMIS utility values to the EQ-5D.
    Hartman JD; Craig BM
    Qual Life Res; 2018 Mar; 27(3):725-733. PubMed ID: 29264776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparing the EQ-5D-5L crosswalks and value sets for England, the Netherlands and Spain: Exploring their impact on cost-utility results.
    Ben Â; Finch AP; van Dongen JM; de Wit M; van Dijk SEM; Snoek FJ; Adriaanse MC; van Tulder MW; Bosmans JE
    Health Econ; 2020 May; 29(5):640-651. PubMed ID: 32059078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.